Compare Ipsen SA with Similar Stocks
Dashboard
1
High Management Efficiency with a high ROE of 20.88%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 41.05
3
Flat results in Jun 25
4
With ROE of 16.44%, it has a Fair valuation with a 2.96 Price to Book Value
5
Market Beating performance in long term as well as near term
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
31.42%
0%
31.42%
6 Months
41.31%
0%
41.31%
1 Year
49.62%
0%
49.62%
2 Years
44.41%
0%
44.41%
3 Years
52.66%
0%
52.66%
4 Years
42.52%
0%
42.52%
5 Years
131.23%
0%
131.23%
Ipsen SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.24%
EBIT Growth (5y)
4.02%
EBIT to Interest (avg)
41.05
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.06
Sales to Capital Employed (avg)
0.74
Tax Ratio
17.35%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
32.49%
ROE (avg)
20.88%
Valuation key factors
Factor
Value
P/E Ratio
18
Industry P/E
Price to Book Value
2.96
EV to EBIT
12.25
EV to EBITDA
7.53
EV to Capital Employed
3.30
EV to Sales
3.32
PEG Ratio
0.61
Dividend Yield
0.91%
ROCE (Latest)
26.95%
ROE (Latest)
16.44%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 3 Foreign Institutions (0.01%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
3,675.90
3,400.60
8.10%
Operating Profit (PBDIT) excl Other Income
1,102.60
1,036.30
6.40%
Interest
36.10
23.10
56.28%
Exceptional Items
-299.40
-285.80
-4.76%
Consolidate Net Profit
444.60
357.30
24.43%
Operating Profit Margin (Excl OI)
203.00%
196.70%
0.63%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 8.10% vs 8.73% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 24.43% vs -42.36% in Dec 2024
About Ipsen SA 
Ipsen SA
Pharmaceuticals & Biotechnology
Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.
Company Coordinates 
Company Details
65 Quai Georges Gorse , BOULOGNE-BILLANCOURT None : 92100
Registrar Details






